Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Nicum S., Brooks CE., Wharton R., Boyle L., Kaye SB., Gourley C., Hall M., Montes A., Pearson SR., Julier P., Midgley RA., Schuh A., Dutton SJ., Grp MC.